A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody

PHASE2CompletedINTERVENTIONAL
Enrollment

221

Participants

Timeline

Start Date

June 18, 2018

Primary Completion Date

June 21, 2019

Study Completion Date

September 12, 2024

Conditions
Multiple Myeloma
Interventions
DRUG

Belantamab mafodotin frozen liquid

Belantamab mafodotin will be available as frozen liquid. Frozen liquid will be available as 30 milligram (mg)/vial solution in a single use vial with unit dose strength of 2.5 or 3.4 mg/kg. Belantamab mafodotin will be administered as IV solution over at least 30 minutes. Frozen belantamab mafodotin will be diluted in 0.9 percent saline and administered via infusion pump.

DRUG

Belantamab mafodotin lyophilized powder

Belantamab mafodotin will be available as lyophilized powder. Lyophilized powder will be available as 100 mg/vial in single-use vial for reconstitution with unit dose strength of 3.4 mg/kg. Lyophilized belantamab mafodotin will be reconstituted using water for injection and diluted with saline before use.

Trial Locations (59)

3004

GSK Investigational Site, Melbourne

3065

GSK Investigational Site, Fitzroy

5011

GSK Investigational Site, Woodville

10029

GSK Investigational Site, New York

10065

GSK Investigational Site, New York

10126

GSK Investigational Site, Torino

18014

GSK Investigational Site, Granada

19049

GSK Investigational Site, Schwerin

19104

GSK Investigational Site, Philadelphia

21201

GSK Investigational Site, Baltimore

28041

GSK Investigational Site, Madrid

28204

GSK Investigational Site, Charlotte

28223

GSK Investigational Site, Madrid

30008

GSK Investigational Site, Murcia

30322

GSK Investigational Site, Atlanta

30342

GSK Investigational Site, Atlanta

30625

GSK Investigational Site, Hanover

31008

GSK Investigational Site, PamplonaNavarra

31059

GSK Investigational Site, Toulouse

33081

GSK Investigational Site, Aviano PN

33600

GSK Investigational Site, Pessac

37007

GSK Investigational Site, Salamanca

37232

GSK Investigational Site, Nashville

43126

GSK Investigational Site, Parma

43210

GSK Investigational Site, Columbus

44093

GSK Investigational Site, Nantes

46017

GSK Investigational Site, Valencia

46202

GSK Investigational Site, Indianapolis

53792

GSK Investigational Site, Madison

55905

GSK Investigational Site, Rochester

56068

GSK Investigational Site, Koblenz

59037

GSK Investigational Site, Lille

60612

GSK Investigational Site, Chicago

60637

GSK Investigational Site, Chicago

66205

GSK Investigational Site, Fairway

69495

GSK Investigational Site, Pierre-Bénite

70121

GSK Investigational Site, Baton Rouge

72076

GSK Investigational Site, Tübingen

75010

GSK Investigational Site, Paris

77030

GSK Investigational Site, Houston

84112

GSK Investigational Site, Salt Lake City

85028

GSK Investigational Site, Rionero in Vulture PZ

97080

GSK Investigational Site, Würzburg

98109

GSK Investigational Site, Seattle

06510

GSK Investigational Site, New Haven

02215

GSK Investigational Site, Boston

T2N 4N2

GSK Investigational Site, Calgary

R3E 0V9

GSK Investigational Site, Winnipeg

M5G 2M9

GSK Investigational Site, Toronto

01307

GSK Investigational Site, Dresden

08916

GSK Investigational Site, Badalona

08036

GSK Investigational Site, Barcelona

B9 5SS

GSK Investigational Site, Birmingham

BH7 7DW

GSK Investigational Site, Bournemouth

NW1 2BU

GSK Investigational Site, London

NG5 1PB

GSK Investigational Site, Nottingham

OX3 7LE

GSK Investigational Site, Oxford

ST4 6QG

GSK Investigational Site, Stoke-on-Trent

SM2 5PT

GSK Investigational Site, Sutton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT03525678 - A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody | Biotech Hunter | Biotech Hunter